Risk-stratified PSA screening is bringing a once-abandoned test back into primary care
Dr. Dereck Mush, MD, MBA
Sera Prognostics
Diagnostic company developing blood tests to predict risk of premature delivery.
What they do
The company develops and markets clinical blood tests that assess the biological risk of premature birth. Its main diagnostic test measures proteins in blood during pregnancy to identify asymptomatic women at high risk of delivering early, enabling obstetricians to implement early clinical interventions.
The record
- Vertical
- Women's Health
- Sub-segment
- Pregnancy risk diagnostics
- Product type
- Diagnostics
- Stage
- Public
- Headquarters
- Salt Lake City, USA
- Region
- North America
- Founded
- 2008
- Total funding
- $135M raised
Notable investors: Blue Ox Healthcare Partners, Domain Associates, Intermountain Healthcare.
Also in Women's Health
Related on The Signal
Dr. Dereck Mush, MD, MBA
Bridging the Last Mile of Acute Cardiology: Synthesized 3D Vectorcardiography at Home
Dr. Dereck Mush, MD, MBA
The $1 Billion Bet on Pre-Symptomatic Medicine: Who Will Own the Longitudinal Baseline?
Dr. Dereck Mush, MD, MBA
Personalized Screening Versus Annual Mammography: What the Evidence Actually Compares
Dr. Dereck Mush, MD, MBA